Zimmer Biomet Holdings, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Zimmer Biomet Holdings, Inc. stock analysis ZBH overview
Bearish -65

Zimmer Biomet Holdings, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire

⚖️ The Portnoy Law Firm has initiated an investigation into possible securities fraud involving Zimmer Biomet Holdings, Inc. (NYSE: ZBH) and may file a class action lawsuit.

📉 Zimmer Biomet's stock price fell $15.63, or 15.2%, to close at $87.55 per share on November 5, 2025.

💰 The company reported net sales of approximately $2 billion for the third quarter of 2025.

📉 Zimmer lowered its full-year organic revenue growth forecast from 4.5% to 4.0% due to regional weakness and market slowdowns.

🌎 Specific areas of weakness include Latin America, emerging markets in Europe, and non-core businesses.

🦴 The U.S. revision market for both hips and knees experienced a modest slowdown persisting throughout the rest of 2025.

🏥 Restorative therapies continued to show weakness during the reporting period.

📞 Investors are encouraged to contact attorney Lesley F. Portnoy at 844-767-8529 or via email for a complimentary case evaluation.

⚠️ The announcement includes standard legal disclaimers noting that prior results do not guarantee similar outcomes.

Bullish Signals
  • Zimmer Biomet reported net sales of approximately $2 billion for the third quarter of 2025, indicating continued revenue generation despite market headwinds.
  • The company maintains a full-year organic revenue growth forecast, albeit lowered from 4.5% to 4.0%, suggesting management still expects positive growth.
Risk Factors
  • Zimmer Biomet's stock price dropped significantly by $15.63 (15.2%) on November 5, 2025, following the release of Q3 2025 financial results.
  • The company explicitly cited weakness in Latin America, emerging markets in Europe, and non-core businesses as drivers for poor performance.
  • Zimmer lowered its full-year organic revenue growth forecast from 4.5% to 4.0%, indicating a downward revision of expectations.
  • A modest slowdown in the U.S. revision market for both hips and knees persisted throughout the rest of 2025, impacting core business segments.
  • Continued weakness in restorative therapies was identified as another factor contributing to the company's financial results.
  • The Portnoy Law Firm has initiated an investigation into possible securities fraud, which introduces legal risk and potential reputational damage.
Full Analysis
The Portnoy Law Firm has announced an investigation into possible securities fraud regarding Zimmer Biomet Holdings, Inc. (NYSE: ZBH) and may file a class action lawsuit on behalf of investors. The firm is soliciting claims from shareholders who suffered losses following a significant stock price decline. Zimmer Biomet's stock fell $15.63, or 15.2%, to close at $87.55 per share on November 5, 2025. This sharp drop occurred after the company released its third quarter 2025 financial results, which reported net sales of approximately $2 billion. The company attributed these results to weakness in Latin America, emerging markets in Europe, and non-core businesses. Consequently, Zimmer lowered the top end of its full-year organic revenue growth forecast from 4.5% to 4.0%, citing a slowdown in the U.S. revision market for hips and knees as well as continued weakness in restorative therapies. The article concludes with standard attorney advertising disclosures stating that prior results do not guarantee similar outcomes, alongside links to other unrelated class action announcements for different companies like GeneDX Holdings and Veritone.